Vericiguat and NT‐proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial

AIMS: Treatment response to vericiguat, based on baseline N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) subgroups specified in the protocol, was evaluated in the heart failure (HF) VICTORIA trial population by post hoc analysis of combined lower three quartiles [Q1–Q3] vs. the upper quartile...

Descripción completa

Detalles Bibliográficos
Autores principales: Senni, Michele, Lopez‐Sendon, Jose, Cohen‐Solal, Alain, Ponikowski, Piotr, Nkulikiyinka, Richard, Freitas, Cecilia, Vlajnic, Vanja Miodrag, Roessig, Lothar, Pieske, Burkert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773767/
https://www.ncbi.nlm.nih.gov/pubmed/35880474
http://dx.doi.org/10.1002/ehf2.14050

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773767/
https://www.ncbi.nlm.nih.gov/pubmed/35880474
http://dx.doi.org/10.1002/ehf2.14050

Ejemplares similares